Capivasertib Emerging Drug Insight and Market Forecast - 2032

“Capivasertib Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Capivasertib for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Capivasertib for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the Capivasertib for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Capivasertib market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Drug Summary

Capivasertib (AZD5363) is a highly potent pan-Akt kinase inhibitor with similar activity against the three isoforms AKT1, AKT2, and AKT3. Capivasertib prevents substrate phosphorylation by AKT and down-regulates the phosphorylation levels of Akt downstream substrates GSK3β and PRAS40 in many cancer cells.

The drug is currently in Phase III trials (CAPItello-292 and CAPItello-291). CAPItello-291 is a combination trial of capivasertib and fluvestrant in 2nd-line and beyond for aromatase inhibitor-resistant locally advanced (inoperable) or metastatic breast cancer. CAPItello-292 is a tri-combination trial of capivasertib with fulvestrant and a CDK4/6 inhibitor in 1st-line early relapse/endocrine therapy resistant locally advanced (inoperable) or metastatic breast cancer.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Capivasertib description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on Capivasertib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Capivasertib research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around Capivasertib.
• The report contains forecasted sales of Capivasertib for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the SWOT analysis with analyst views for Capivasertib in ER+ve HER2-ve Breast Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Capivasertib Analytical Perspective

In-depth Capivasertib Market Assessment

This report provides a detailed market assessment of Capivasertib in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2024 to 2032.

Capivasertib Clinical Assessment

The report provides the clinical trials information of Capivasertib in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Capivasertib dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to Capivasertib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Capivasertib in ER+ve HER2-ve Breast Cancer.
• This in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Capivasertib in ER+ve HER2-ve Breast Cancer.  

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Capivasertib?
• What is the clinical trial status of the study related to Capivasertib in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Capivasertib development?
• What are the key designations that have been granted to Capivasertib for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of Capivasertib for ER+ve HER2-ve Breast Cancer?
• What are the forecasted sales of Capivasertib in the United States?
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to Capivasertib for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?

This product will be delivered within 2 business days.